Flag of the European Union EU Clinical Trials Register Help

Clinical trials for International prostate symptom score

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: International prostate symptom score. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-005232-33 Sponsor Protocol Number: FE200486 CS30 Start Date*: 2009-04-15
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients o...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-008604-40 Sponsor Protocol Number: FE200486 CS31 Start Date*: 2009-04-09
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with pro...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) FI (Completed) DK (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001073-94 Sponsor Protocol Number: TH CR-202 Start Date*: 2005-12-27
    Sponsor Name:Threshold Pharmaceuticals Inc
    Full Title: A Randomised Phase 3, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
    Medical condition: Benign Prostatic Hyperplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004338-26 Sponsor Protocol Number: FE200486 CS28 Start Date*: 2008-11-18
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: Ensayo clínico abierto, aleatorizado, de grupos paralelos que compara degarelix frente a bloqueo androgénico combinado (goserelina + bicalutamida) en términos de reducción de la puntuación en la es...
    Medical condition: Cáncer de próstata
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed) GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000946-16 Sponsor Protocol Number: TryptoBPH Start Date*: 2021-12-17
    Sponsor Name:Centro Clínico Académico - Braga, Associação (2CA-Braga)
    Full Title: TryptoBPH - Proof-of-concept study to evaluate the safety and efficacy of tryptophan in patients with BPH
    Medical condition: Benign Prostate Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10065030 BPH LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000848-83 Sponsor Protocol Number: CSO181 Start Date*: 2005-07-06
    Sponsor Name:GlaxoSmithKline Consumer Healthcare GmbH & Co KG, 77815 Bühl
    Full Title: Teilverblindete, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Wirksamkeit von Dickextrakt aus Kürbissamen (Kürbissamen-Extrakt) und Kürbissamen bei Patienten mit benigner Prosta...
    Medical condition: benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10004446 LLH
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003578-24 Sponsor Protocol Number: FE 200486 CS25 Start Date*: 2008-06-30
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign pro...
    Medical condition: Patients with Benign Prostata Hypertropia (BPH) who fulfil the following criteria: a prostate volume of more than 30 mL, maximal uroflow of 12 mL/s or less; International Prostate Symptom Score (IP...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004447 Benign prostatic hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012325-11 Sponsor Protocol Number: FE 200486 CS36 Start Date*: 2009-10-21
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated...
    Medical condition: Bening Prostate Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    12.0 10014840 Enlarged prostate (benign) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) GB (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004422-17 Sponsor Protocol Number: ANDRO-AOUC-2014-1 Start Date*: 2015-04-14
    Sponsor Name:UNIVERSITY OF FLORENCE
    Full Title: Double-blinded placebo-controlled study on men with lower urinary tract symptoms secondary to prostatic hyperplasia (LUTS-BPH) to assess changes in pressure flow study (PFS) and in molecular profil...
    Medical condition: lower urinary tract symptoms/benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038359 - Renal and urinary disorders 10071289 Lower urinary tract symptoms PT
    17.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004281-17 Sponsor Protocol Number: 191622-517 Start Date*: 2007-12-18
    Sponsor Name:Allergan Inc.
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Com...
    Medical condition: Patients with lower urinary tract symptoms due to Benign Prostatic Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) IT (Completed) GB (Completed) CZ (Completed) AT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-002841-21 Sponsor Protocol Number: H6D-MC-LVHJ(a) Start Date*: 2008-10-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of B...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001333-88 Sponsor Protocol Number: FP01C-17-001 Start Date*: 2017-08-23
    Sponsor Name:Foresee Pharmaceuticals Co., Ltd.
    Full Title: An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects with Prostate Cancer
    Medical condition: Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-020604-29 Sponsor Protocol Number: H6D-CR-LVIW(a), Addendum 1 u.4 Start Date*: 2010-11-05
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020172-30 Sponsor Protocol Number: 191622-100 Start Date*: 2010-08-16
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neur...
    Medical condition: Treatment of Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002504-43 Sponsor Protocol Number: LPC-004 Start Date*: 2016-12-30
    Sponsor Name:LIDDS AB
    Full Title: A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Ass...
    Medical condition: Asymptomatic localized prostate cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000154-76 Sponsor Protocol Number: BXL628 02 14 Start Date*: 2005-03-16
    Sponsor Name:BIOXELL SPA
    Full Title: A randomized, double blind, double dummy, placebo controlled, parallel group study to determine the effect of BXL628 in monotherapy 75 mcg and 150 mcg and in combination 150 mcg with tamsulosi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10004446 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002047-26 Sponsor Protocol Number: FDC116115 Start Date*: 2012-10-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: FDC116115: A prospective study of sexual function in sexually active men treated for BPH
    Medical condition: BPH (Benign prostatic hyperplasia)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    15.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed) NL (Completed) HU (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002451-41 Sponsor Protocol Number: NX1207-IT-CL0414 Start Date*: 2013-08-21
    Sponsor Name:Recordati S.p.A.
    Full Title: EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLI...
    Medical condition: LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) PT (Prematurely Ended) ES (Prematurely Ended) GB (Completed) IT (Prematurely Ended) PL (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005665-11 Sponsor Protocol Number: KMD3213-IT-CL 0215 Start Date*: 2006-03-23
    Sponsor Name:Recordati S.p.A
    Full Title: Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Cont...
    Medical condition: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004446 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022111-19 Sponsor Protocol Number: FDC114615 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:41:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA